目的　评价美洛昔康 /萘丁美酮治疗类风湿关节炎的疗效和安全性。方法　随机对照、双盲的比较研究。共完成病例12 0例 (美洛昔康 5 9例 ;萘丁美酮 6 1例 )。po美洛昔康 15mg每天一次或萘丁美酮 10 0 0mg每天一次 ,疗程 4周 ,其中 41例患者连用 8周。结果　 4,8周时美洛昔康总有效率为 6 9.5 % ,95 .0 % ;萘丁美酮为 6 7.2 % ,90 .5 % ,两药均能显著改善患者的症状和体征 ,降低血沉。 8周时美洛昔康改善患者的休息痛和关节压痛指数两项优于萘丁美酮 (P <0 .0 5 )。安全性评价 :美洛昔康不良反应发生率 :10 .2 % ;萘丁美酮 18.0 % ,统计分析两药的耐受性无明显差异。不良反应以消化道症状为主 ,无因不良反应停药病例。结论　美洛昔康和萘丁美酮治疗类风湿关节炎的疗效和安全性相似 Objective To evaluate the efficacy and safety of meloxicam / nabumetone in the treatment of rheumatoid arthritis. Methods Randomized, double-blind comparative study. A total of 120 cases were completed (meloxicam 59; nabumetone 61). po meloxicam 15mg once daily or nabumetone 10 0mg once daily for 4 weeks, 41 of them for 8 weeks. Results At 4 and 8 weeks, the total effective rate of meloxicam was 6 9.5% and 95.0% respectively. Nabumetone was 6 7.2% and 90.5% respectively. Both drugs could significantly improve the symptoms and signs of patients and reduce the erythrocyte sedimentation rate. Resting pain and joint tenderness index of meloxicam at 8 weeks were better than nabumetone (P <0.05). Safety evaluation: The incidence of adverse reactions of meloxicam: 10.2%; nabumetone 18.0%, statistical analysis of the two drugs no significant difference in tolerance. Adverse reactions to gastrointestinal symptoms, no cases of adverse drug withdrawal. Conclusion The efficacy and safety of meloxicam and nabumetone in treatment of rheumatoid arthritis are similar